NCT00381173.

Trial name or title	A phase I open‐label study of the safety and feasibility of ZYC300 administration with cyclophosphamide pre‐dosing
Methods	Phase I
Participants	22 advanced‐stage malignancies with evidence of disease and no therapeutic options
Interventions	IM ZYC300 (a plasmid DNA formulated within biodegradable microencapsulated particles) with IV cyclophosphamide
Outcomes	Safety Immune responses Tumour responses
Starting date	November 2006
Contact information
Notes	Study completion January 2009; no published records available